Eledon Pharmaceuticals to Participate in Two Upcoming Conferences

Rhea-AI Summary

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced participation in two upcoming conferences. On October 6, Steven Perrin, Ph.D., will engage in a panel discussion on ALS treatment at the Cantor Neurology & Psychiatry Conference. On October 7, Jeff Bornstein, M.D., will present on the safety and efficacy of tegoprubart for ALS patients at the ALS One 5th Annual ALS Research Symposium. Both presentations are exclusive to registered attendees. Eledon focuses on developing therapies targeting the CD40L pathway for organ transplant, autoimmune diseases, and ALS.

IRVINE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that senior management will participate in two upcoming conferences:

• A panel discussion with Steven Perrin, Ph.D., President and Chief Scientific Officer, titled “ALS -- New Treatment Paradigm with More MoAs on the Way?” at the Cantor Neurology & Psychiatry Conference on Thursday, October 6, 2022 at 1:20 p.m. ET; and
  
  
• An oral presentation by Jeff Bornstein, M.D., Chief Medical Officer, titled "Tegoprubart (AT-1501) is safe and well tolerated and reduces inflammation in patients with ALS” at the ALS One 5^th Annual ALS Research Symposium on Friday, October 7, 2022 at 11:40 a.m. ET.
  

Both presentations will be available to registered conference attendees only. For additional information or to request a meeting with management, please contact conference representatives.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

FAQ

What conferences will Eledon Pharmaceuticals participate in?

Eledon Pharmaceuticals will participate in the Cantor Neurology & Psychiatry Conference on October 6 and the ALS One 5th Annual ALS Research Symposium on October 7, 2022.

Who will speak at the Cantor Neurology & Psychiatry Conference?

Steven Perrin, Ph.D., will speak on ALS treatment paradigms at the Cantor Neurology & Psychiatry Conference.

What will be discussed at the ALS One Research Symposium?

Jeff Bornstein, M.D., will present data on the safety and inflammation reduction of tegoprubart in ALS patients at the ALS One Research Symposium.

What is tegoprubart?

Tegoprubart is Eledon's lead compound, an anti-CD40L antibody in development for treating ALS and other conditions.

When will the presentations from Eledon Pharmaceuticals be available?

The presentations will be available exclusively to registered attendees of the respective conferences.